Regular Aspirin Use May Lower Breast Cancer Risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirin or ibuprofen) regularly for 5 years or more had a 40% lower risk of breast cancer than those who did not report such use, Dr. Randall E. Harris and his colleagues at the Ohio State University Comprehensive Cancer Center have found.

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirinor ibuprofen) regularly for 5 years or more had a 40% lower riskof breast cancer than those who did not report such use, Dr. RandallE. Harris and his colleagues at the Ohio State University ComprehensiveCancer Center have found.

This case-control study involved 303 breast cancer patients diagnosedat the University's Arthur G. James Cancer Hospital and 906 controls(women who underwent screening mam-mography and had no detectablebreast disease). Risk factor data were collected by personal interviewsat the time of diagnosis or screening.

Significantly more women in the control group (27%) reported regularNSAID use than did the breast cancer patients (19%). Calculationof odds ratios showed a reduction in risk of 36% for those whotook NSAIDs three or more times a week for 6 months or more, anda reduction of 40% among those who used NSAIDs seven times a weekfor 5 years or more.

These results, published in Oncology Reports (2:591-592, 1995),are supported by an earlier study by Dr. Harris' team that matched744 newly diagnosed breast cancer patients with 767 controls drawnfrom hospital patients with medical conditions unrelated to breastcancer.

That study found a 37% reduction in breast cancer risk among womenwho reported using NSAIDs at least three times a week for at least5 years (Prev Med 24:119-120, 1995).

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content